Exercise may be as effective as medicines in hypertension
Using data from nearly 40,000 people, researchers found that the effect of exercise on systolic blood pressure in hypertensive people was similar to angiotensin converting enzyme inhibitors, angiotensin-2 receptor blockers, beta blockers and diuretics.
Exercise interventions are as effective as many antihypertensive medicines in reducing systolic blood pressure (SBP) in people with hypertension, according to the results of a network meta-analysis published in the British Journal of Sports Medicine (18 December 2018).
The researchers looked at results from 197 randomised controlled trials evaluating exercise interventions, which were divided into four categories — endurance, dynamic resistance, isometric resistance and a combination of endurance and dynamic resistance — and 194 evaluating antihypertensive medications. The trials involved nearly 40,000 participants.
They found that, overall, antihypertensive medicines were associated with greater reductions in SBP than exercise interventions (mean difference -3.96 mmHg, 95% credible interval -5.02 to -2.91). But, when they restricted the analyses to trials that only included hypertensive individuals, endurance and dynamic resistance exercise were as effective as angiotensin converting enzyme inhibitors, angiotensin-2 receptor blockers, beta blockers and diuretics in reducing SBP.
However, the team noted that the effect of exercise interventions on SBP remained understudied in relation to commonly used medicines. Only 56 exercise intervention trials included individuals with hypertension.
“The SBP-lowering effect of exercise among hypertensive populations appears similar to that of commonly used antihypertensive medications,” they wrote.
“Generalisability of these findings to real-world clinical settings should be further evaluated.”
Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20205960
Recommended from Pharmaceutical Press
Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£138.50
Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£262.50
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.£40.00
A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.£33.00
All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.£27.00